Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Bloomberg Customers

Markets & Finance

Goldman Ups Barr Pharmaceuticals to Outperform

Goldman Sachs upgraded Barr Pharmaceuticals (BRL) to outperform from in-line.

Analyst Randall Stanicky says the pharmaceutical company has a visible long-term growth story, with identifiable upside to his above-consensus earnings per share (EPS) estimates. He notes growing contribution from the company's proprietary products (38% of its 2007 gross profit,) and thinks this represents a shift which may garner premium valuation going forward. He says the company's recent share price weakness may be partly linked to concerns over a potential deal with Mylan Laboratories (MYL), but he views this combination as unlikely. He sees fair value in the low- to mid-$70s.

blog comments powered by Disqus